Formulation and In-Vitro Evaluation of Folic Acid Conjugated Multiwalled Carbon Nanotubes For The Targeting of Cancer
Keywords:
N\AAbstract
Cancer remains one of the leading causes of mortality worldwide, necessitating the development of targeted and efficient drug delivery systems. Multiwalled carbon nanotubes (MWCNTs) have emerged as promising nanocarriers due to their high surface area, chemical stability, and potential for functionalization. This study aims to formulate and evaluate folic acid-conjugated MWCNTs (FA-MWCNTs) for targeted cancer therapy. Folic acid, a high-affinity ligand for folate receptors overexpressed on many cancer cells, was conjugated to MWCNTs to enhance site-specific drug delivery while minimizing off-target effects.
The MWCNTs were functionalized with carboxyl groups and subsequently conjugated with folic acid using a covalent coupling method. The conjugation was confirmed through Fourier-transform infrared (FTIR) spectroscopy, x ray diffraction (XRD), and raman spectroscopy. The drug-loading capacity of the FA-MWCNTs was evaluated using a model chemotherapeutic agent, demonstrating significant encapsulation efficiency. In-vitro cytotoxicity studies were performed on folate receptor-positive and receptor-negative cancer cell lines to assess the targeting efficiency. Results revealed that FA-MWCNTs exhibited enhanced cellular uptake and selective toxicity towards folate receptor-positive cancer cells compared to non-targeted MWCNTs.
Additionally, the drug release profile indicated a sustained release mechanism, ensuring prolonged therapeutic effects. The findings highlight the potential of FA-MWCNTs as a targeted drug delivery system with promising applications in cancer therapy. Further in-vivo studies are recommended to evaluate the pharmacokinetics, biodistribution, and safety of this novel formulation for clinical translation.
Downloads
References
E. V. Emeihe, E. I. Nwankwo, M. D. Ajegbile, J. A. Olaboye, and C. C. Maha, “Revolutionizing drug delivery systems: Nanotechnology-based approaches for targeted therapy,” Int. J. Life Sci. Res. Arch., vol. 7, no. 1, pp. 40–58, 2024.
N. Gupta, S. M. Gupta, and S. K. Sharma, “Carbon nanotubes: Synthesis, properties and engineering applications,” Carbon Lett., vol. 29, pp. 419–447, 2019.
S. Rathinavel, K. Priyadharshini, and D. Panda, “A review on carbon nanotube: An overview of synthesis, properties, functionalization, characterization, and the application,” Mater. Sci. Eng. B, vol. 268, p. 115095, 2021.
E. I. Bîru and H. Iovu, “Graphene nanocomposites studied by Raman spectroscopy,” Raman Spectrosc, vol. 9, p. 179, 2018.
D. Cui, “Advances and prospects on biomolecules functionalized carbon nanotubes,” J. Nanosci. Nanotechnol., vol. 7, no. 4–5, pp. 1298–1314, 2007.
S. Merum, J. B. Veluru, and R. Seeram, “Functionalized carbon nanotubes in bio-world: Applications, limitations and future directions,” Mater. Sci. Eng. B, vol. 223, pp. 43–63, 2017.
G. B. Ramesh, P. Singh, and K. Biswas, “Potentialities of Bio-functionalized Carbon Nanotubes for Different Anti-cancerous Activities,” J. Inorg. Organomet. Polym. Mater., pp. 1–26, 2024.
R. Jha, A. Singh, P. K. Sharma, and N. K. Fuloria, “Smart carbon nanotubes for drug delivery system: A comprehensive study,” J. Drug Deliv. Sci. Technol., vol. 58, p. 101811, 2020.
C. Pucci, C. Martinelli, and G. Ciofani, “Innovative approaches for cancer treatment: Current perspectives and new challenges,” Ecancermedicalscience, vol. 13, 2019.
E. Moysan, G. Bastiat, and J.-P. Benoit, “Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications,” Mol. Pharm., vol. 10, no. 2, pp. 430–444, 2013.
H. Han et al., “Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy,” Asian J. Pharm. Sci., vol. 17, no. 1, pp. 35–52, 2022.
C. Manegold, “Gemcitabine (Gemzar®) in non-small cell lung cancer,” Expert Rev. Anticancer Ther., vol. 4, no. 3, pp. 345–360, 2004.
M. Estanqueiro, M. H. Amaral, J. Conceição, and J. M. S. Lobo, “Nanotechnological carriers for cancer chemotherapy: the state of the art,” Colloids surfaces B Biointerfaces, vol. 126, pp. 631–648, 2015.
C. K. Thakur et al., “Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery,” Front. Pharmacol., vol. 15, 2024, [Online]. Available: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1417399
K. Halwai, S. Khanna, G. Gupta, S. Wahab, M. Khalid, and P. Kesharwani, “Folate-conjugated carbon nanotubes as a promising therapeutic approach for targeted cancer therapy,” J. Drug Target., pp. 1–16, 2024.
J. Soleymani, M. Hasanzadeh, M. H. Somi, and A. Jouyban, “The role of nanomaterials on the cancer cells sensing based on folate receptor: analytical approach,” TrAC Trends Anal. Chem., vol. 125, p. 115834, 2020.
Y. Lu, E. Sega, C. P. Leamon, and P. S. Low, “Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential,” Adv. Drug Deliv. Rev., vol. 56, no. 8, pp. 1161–1176, 2004.
R. Krishnamurthy and M. C. Manning, “The stability factor: importance in formulation development,” Curr. Pharm. Biotechnol., vol. 3, no. 4, pp. 361–371, 2002.
D. Zhou, “Understanding physicochemical properties for pharmaceutical product development and manufacturing II: physical and chemical stability and excipient compatibility,” J. Valid. Technol., vol. 15, no. 3, p. 36, 2009.
M. Davoren et al., “In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells,” Toxicol. Vitr., vol. 21, no. 3, pp. 438–448, 2007, doi: https://doi.org/10.1016/j.tiv.2006.10.007.
G. D. Souto, Z. Farhane, A. Casey, E. Efeoglu, J. McIntyre, and H. J. Byrne, “Evaluation of cytotoxicity profile and intracellular localisation of doxorubicin-loaded chitosan nanoparticles,” Anal. Bioanal. Chem., vol. 408, pp. 5443–5455, 2016.
K. M. Yap et al., “Drug delivery of natural products through nanocarriers for effective breast cancer therapy: A comprehensive review of literature,” Int. J. Nanomedicine, pp. 7891–7941, 2021.
K. C. Waterman and R. C. Adami, “Accelerated aging: prediction of chemical stability of pharmaceuticals,” Int. J. Pharm., vol. 293, no. 1–2, pp. 101–125, 2005.
A. Khan, A. Tripathi, M. Gandhi, J. Bellare, and R. Srivastava, “Development of injectable upconversion nanoparticle‐conjugated doxorubicin theranostics electrospun nanostructure for targeted photochemotherapy in breast cancer,” J. Biomed. Mater. Res. Part A, 2024.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
